Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2022

01-02-2022 | Public Health | The Global Epidemic (S Vermund, Section Editor)

HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups

Authors: D. K. Nomah, J. Reyes-Urueña, J. M. Llibre, J. Ambrosioni, F. S. Ganem, J. M. Miró, J. Casabona

Published in: Current HIV/AIDS Reports | Issue 1/2022

Login to get access

Abstract

Purpose of Review

The purpose of this review is to use the currently available clinical and epidemiological data, to identify key aspects to improve both the clinical management and public health response to SARS-CoV-2/HIV co-infection among HIV vulnerable populations and people living with HIV (PLWH).

Recent Findings

While at the beginning of the COVID-19 pandemic, the lack of robust information on SARS-CoV-2/HIV co-infection, prevented a clear picture of the synergies between them, currently available data strongly support the importance of common structural factors on both the acquisition and clinical impact of these infections and the relevance of age, comorbidities, and detectable HIV viral load as associated worse prognostic factors among PLWH.

Summary

Although more information is needed to better understand the biological, clinical, and epidemiological relationship between both infections, a syndemic approach to prevent SARS-CoV-2 among HIV high-risk groups and PLWH, targeting these populations for SARS-CoV-2 vaccines and protocolizing early identification of PLWH with worse COVID-19 prognosis factors, is crucial strategies to decrease the overall impact of SARS-CoV-2 /HIV co-infection.
Literature
1.
2.
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.PubMedPubMedCentral
3.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–6.PubMed
4.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.PubMedPubMedCentral
5.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.PubMed
6.
Sachs JD, Horton R, Bagenal J, Ben AY, Caman OK, Lafortune G. The lancet COVID-19 commission. Lancet. 2020;396:454–5.PubMedPubMedCentral
7.
Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev. 2013;254:114–42.PubMedPubMedCentral
8.
Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sighem A, de Wolf F, Hallett TB. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–8.PubMedPubMedCentral
9.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.PubMed
10.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824–35.PubMed
11.
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49:717–26.PubMed
12.
13.
Tesoriero JM, Swain C-AE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4:e2037069–e2037069.PubMedPubMedCentral
14.
Vizcarra P, Pérez-Elías MJMJMJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;3018:1–11.
15.
16.
Cooper T, Woodward B, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020;21:567–77.PubMed
17.
Bhaskaran K, Rentsch CT, MacKenna B, et al (2021) HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 8:e24–e32. In this large study in UK, HIV infection was identified as an independent risk factor for poor outcomes in PLWH, also after correction for relevant vairables. However, relevant data (such as CD4 cell count) was were not reported.
18.
19.
Bertagnolio S, Thwin S, Silva R, Ford N, Baggaley R, Vitoria M, Jassat W, Doherty M Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform. 11th IAS Conf. HIV Sci. | 18-21 July 2021. PEBLB20. In this WHO report with more than 160000 COVID-19 patients hospitalized (more than 15000 PLWH), HIV infection was associated with poor outcome (severe disease and death). More than 90% of PLWH were from South Africa, data on ART was only reported for 40% of participants, and CD4 cell count was not reported.
20.
Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis. 2020. https://​doi.​org/​10.​1093/​cid/​ciaa1605.CrossRefPubMedCentral
21.
Hoffmann C, Casado JL, Härter G, et al (2020) Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV. HIV Med 1–7
22.
Nomah D, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo R Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV (in press)
23.
Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin Infect Dis. 2020;65212:1–9.
24.
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787–99.PubMed
25.
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, another inexpensive, well-Known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals. 2021;14:454.PubMedPubMedCentral
26.
27.
28.
Sun S, Hou J, Chen Y, Lu Y, Brown L, Operario D. Challenges to HIV care and psychological health during the COVID-19 pandemic among people living with HIV in China. AIDS Behav. 2020;24:2764–5.PubMedPubMedCentral
29.
Joint United Nations Programme on HIV/AIDS (UNAIDS). (2021) Fact sheet 2021. Preliminary UNAIDS 2021 epidemiological estimates. GLOBAL HIV STATISTICS.
30.
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. (2020) HIV/AIDS surveillance in Europe 2020. 2019 data.
31.
Stoecklin SB, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, Mechain M, Meurice L, Nguyen M, Bassi C. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Eurosurveillance. 2020;25:2000094.
32.
33.
Vestergaard LS, Nielsen J, Richter L, Schmid D, Bustos N, Braeye T, Denissov G, Veideman T, Luomala O, Möttönen T (2020) Excess all-cause mortality during the COVID-19 pandemic in Europe–preliminary pooled estimates from the EuroMOMO network, March to April 2020. Eurosurveillance 25:2001214. The study presented preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March–April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths).
34.
Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, Atzori C, Ridolfo A, Cattaneo D (2020) Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis ciaa579
35.
Inciarte A, Gonzalez-Cordon A, Rojas J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS. 2020;34:1775–80.PubMed
36.
Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, Miro JM. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314–6.PubMedPubMedCentral
37.
Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, Du P. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11:1–12.
38.
Cabello A, Zamarro B, Nistal S, Victor V, Hernández J, Prieto-Pérez L, Carrillo I, Álvarez B, Fernández-Roblas R, Hernández-Segurado M. COVID-19 in people living with HIV: a multicenter case-series study. Int J Infect Dis. 2021;102:310–5.PubMed
39.
Kowalska JD, Kase K, Vassilenko A, Harxhi A, Lakatos B, Lukić GD, Verhaz A, Yancheva N, Dumitrescu F, Jilich D. The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease—a report from Central and Eastern Europe. Int J Infect Dis. 2021;104:293–6.PubMed
40.
Di Biagio A, Ricci E, Calza L, Squillace N, Menzaghi B, Rusconi S, Orofino G, Bargiacchi O, Molteni C, Valsecchi L. Factors associated with hospital admission for COVID-19 in HIV patients. AIDS. 2020;34:1983–5.PubMed
41.
Etienne N, Karmochkine M, Slama L, Pavie J, Batisse D, Usubillaga R, Letembet V-A, Brazille P, Canouï E, Slama D. HIV infection and COVID-19: risk factors for severe disease. AIDS. 2020;34:1771.PubMed
42.
Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, Juniper T, Taylor C (2020) Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. Clin Infect Dis 1–2
43.
Silverman JD, Hupert N, Washburne AD (2020) Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States. Sci. Transl. Med. 12:
44.
Coma E, Mora N, Prats-Uribe A, Fina F, Prieto-Alhambra D, Medina-Peralta M (2020) Excess cases of influenza suggest an earlier start to the coronavirus epidemic in Spain than official figures tell us: an analysis of primary care electronic medical records from over 6 million people from Catalonia. Medrxiv
45.
Peixoto VR, Nunes C, Abrantes A. Epidemic surveillance of COVID-19: considering uncertainty and under-ascertainment. Port J Public Heal. 2020;38:23–9.
46.
Muñoz B, Buti M, VAzquez I Tenofovir reduces severity of COVID-19 infection in chronic hepatitis B patients. EASL Int. Liver Congr. June 23–26, 2021. Abstr. PO-1449.
47.
48.
Delaugerre C, Assoumou L, Maylin S SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine-based PrEP in 2020: a sub-study of PREVENIR-ANRS and SAPRIS-Sero. IAS 2021, 11th IAS Conf. HIV Sci. July 18–21, 2021. Abstr. OAC0201.
49.
Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13:5.PubMedPubMedCentral
50.
Ambrosioni J, Blanco JL, Reyes-urueña JM, Davies M, Sued O, Marcos MA, Martínez E. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8:294–305.
51.
52.
World Health Organization (WHO) (2021) Expanding our understanding of post COVID-19 condition: report of a WHO webinar, 9 February 2021.
53.
Lee K-Y, Tsai M-S, Kuo K-C, Tsai J-C, Sun H-Y, Cheng AC, Chang S-Y, Lee C-H, Hung C-C. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2014;10:3700–10.PubMedPubMedCentral
54.
Ceravolo A, Orsi A, Parodi V, Rosselli R, Ansaldi F. Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. J Prev Med Hyg. 2013;54:1.PubMedPubMedCentral
55.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15.PubMed
56.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB (2020) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med.
57.
Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV. Clin Infect Dis. 2021 Jul 22;ciab648. doi: https://​doi.​org/​10.​1093/​cid/​ciab648. Online ahead of print.
58.
Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA (2021) Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. This study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in 54 individuals with HIV. The conclusions were that in virologically suppressed white men on ART and more than 350 cells/mm3, the magnitude and persistence of SARS-CoV-2 spike-specific humoral or cellular responses at short term (2 months) were similar to that seen in HIV-negative participants. In addition, vaccination was safe without any serious adverse events.
59.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384:1899–909.PubMedPubMedCentral
60.
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–93.PubMedPubMedCentral
61.
Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–54.PubMedPubMedCentral
62.
Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet. 2020;396:e68–9.PubMedPubMedCentral
63.
64.
Joint UN Programme on HIV/AIDS (UNAIDS) (2021) Statement of the Joint UN Programme on HIV/AIDS (UNAIDS) Interagency Working Group on Key Populations on the need to ensure access to quality, safe, and non-discriminatory services for HIV key populations and migrants in the context of the COVID-19 pandem.
65.
Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24:2244–9.PubMedPubMedCentral
66.
Algarin AB, Varas-Rodríguez E, Valdivia C, Fennie KP, Larkey L, Hu N, Ibañez GE. Symptoms, stress, and HIV-related care among older people living with HIV during the COVID-19 pandemic, Miami, Florida. AIDS Behav. 2020;24:2236–8.PubMedPubMedCentral
67.
Santos G-M, Ackerman B, Rao A, et al. Economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response on a global sample of cisgender gay men and other men who have sex with men. AIDS Behav. 2021;25:311–21.PubMed
68.
Jones DL, Morgan KE, Martinez PC, Rodriguez VJ, Vazquez A, Raccamarich PD, Alcaide ML. COVID-19 burden and risk among people with HIV. J Acquir Immune Defic Syndr. 2021;87:869–74.PubMedPubMedCentral
69.
Tomar A, Spadine MN, Graves-Boswell T, Wigfall LT. COVID-19 among LGBTQ+ individuals living with HIV/AIDS: psycho-social challenges and care options. AIMS Public Heal. 2021;8:303–8.
70.
Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the impact of COVID-19 on men who have sex with men across the United States in April, 2020. AIDS Behav. 2020;24:2024–32.PubMed
71.
Stephenson R, Chavanduka TMD, Rosso MT, Sullivan SP, Pitter RA, Hunter AS, Rogers E. Sex in the time of COVID-19: results of an online survey of gay, bisexual and other men who have sex with men’s experience of sex and HIV prevention during the US COVID-19 epidemic. AIDS Behav. 2021;25:40–8.PubMed
72.
Hochstatter KR, Akhtar WZ, Dietz S, et al. Potential influences of the COVID-19 pandemic on drug use and HIV care among people living with HIV and substance use disorders: experience from a pilot mHealth intervention. AIDS Behav. 2021;25:354–9.PubMed
73.
Dorward J, Khubone T, Gate K, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. Lancet HIV. 2021;8:e158–65.PubMedPubMedCentral
74.
Ridgway JP, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M, Pitrak D. HIV care continuum and COVID-19 outcomes among people living with HIV during the COVID-19 pandemic, Chicago, IL. AIDS Behav. 2020;24:2770–2.PubMedPubMedCentral
75.
Adadi P, Kanwugu ON. Living with HIV in the time of COVID-19: a glimpse of hope. J Med Virol. 2021;93:59–60.PubMed
76.
Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, et al. HIV care in times of the COVID-19 crisis — where are we now in Central and Eastern Europe? Int J Infect Dis. 2020;96:311–4.PubMedPubMedCentral
77.
Simões D, Stengaard AR, Combs L, Raben D (2020) Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020. Eurosurveillance 25:2001943. This study is a European effort to assess the impact of the first year of the pandemic on HIV services, including community based, healthcare, and laboratories.
78.
Castel AD, Wilbourn B, Magnus M, Greenberg AE. SARS-CoV-2 and HIV: epidemiology, treatment, and lessons learned from HIV. AIDS Rev. 2020;22:133–42.PubMed
79.
Marhefka S, Lockhart E, Turner D. Achieve research continuity during social distancing by rapidly implementing individual and group videoconferencing with participants: key considerations, best practices, and protocols. AIDS Behav. 2020;24:1983–9.PubMedPubMedCentral
Metadata
Title
HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups
Authors
D. K. Nomah
J. Reyes-Urueña
J. M. Llibre
J. Ambrosioni
F. S. Ganem
J. M. Miró
J. Casabona
Publication date
01-02-2022
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2022
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00596-5

Other articles of this Issue 1/2022

Current HIV/AIDS Reports 1/2022 Go to the issue

Central Nervous System and Cognition (SS Spudich, Section Editor)

Central Nervous System Impact of Perinatally Acquired HIV in Adolescents and Adults: an Update

The Global Epidemic (S Vermund, Section Editor)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa

Central Nervous System and Cognition (SS Spudich, Section Editor)

Emerging Single-cell Approaches to Understand HIV in the Central Nervous System

The Global Epidemic (S Vermund, Section Editor)

HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

The Reproductive Transition: Effects on Viral Replication, Immune Activation, and Metabolism in Women with HIV infection

The Global Epidemic (S Vermund, Section Editor)

Social Determinants of Disease: HIV and COVID-19 Experiences
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits